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Introduction
Breast cancer is the most diagnosed cancer in women, especially 
post-menopausic, with a mortality rate of nearly 20%, and a 
growing incidence.1  Approximately 70% of the detected tumors 
express the estrogen receptor (ER).  Tamoxifen (TAMO), a 
non-steroidal triphenylethylene antiestrogen drug, was approved 
in 1977 by Food and Drug Administration for adjuvant treatment 
against metastasis breast cancer, with impressive results.2 
Tamoxifen competitively inhibits oestradiol binding to the 
estrogen receptor, starving the cancer cells, and preventing 
tumor growth.3  Currently, it is the endocrine therapy of choice 
for all stages of ER-positive breast cancer,4 and is also prescribed 
as a chemopreventive therapeutic agent to women with high 
risk of developing this disease.5  However, TAMO treatment has 
also several problems, as adverse side effects, doubtful long-term 
safety,6 strong variability in response,7 and development of 
tumour resistance, leading to relapse.8  Moreover, a decrease of 
survival rate has been associated to a lack of compliance with 
adjuvant TAMO therapy.9
Tamoxifen is a weak base, with a value of minus logarithm of 
the basic dissociation constant (pKb) of 5.1 and highly 
hydrophobic, according to the value of the logarithm of the 
partition coefficient octanol/water (log Po/w), 6.64, with low 
solubility in water.10  It is converted to its citrate salt for 
commercial purposes, to increase the aqueous solubility and 
therapeutic efficacy.11  Thus, TAMO is supplied in 
pharmaceuticals as oral tablets of TAMO citrate, with a 
molecular weight (MW) of 563.4 g/mol.  It is a white, odourless 
and fine crystalline powder, moderately soluble in water 
(0.5 mg/mL) and in acid (0.2 mg/mL).12  Pharmaceutical 
producers have to check that the TAMO formulations contain 
the amount of active principle indicated in the label.  Besides, 
TAMO therapy is long-term; therefore some patients are enticed 
to initially purchase a large amount of tablets and, improving 
the risk to take the last ones after the expiration date, and then 
containing a non-reliable amount of TAMO.13  Due to the high 
price of formulations and the long duration of the treatment, the 
overall cancer therapy is extremely expensive.  This has 
encouraged the production of generic formulations, especially in 
developing countries, by non-certified trade marks.  The quality 
of these generics must be rigorously controlled and assured 
prior to their distribution by medical stores.14  In some cases, 
counterfeit formulations with doubtful quality are produced in 
illegal laboratories, and are offered at minor cost on the black 
market as legitimate tablets.15,16  Since the dose can affect the 
final outcome of the treatment and side effects, the amount of 
active principle in tablets must be accurately known.3  For these 
reasons, clinicians and pharmacist must dispose of reliable 
methods to quantify tamoxifen in commercial pharmaceutical 
formulations.
A limited amount of analytical methods have been developed 
to analyze TAMO in formulations.  UV-Visible spectrophotometry 
has been proposed as a rapid method to quantify TAMO, prior 
absorbance enhancing by complexation17,18 or derivatization 
with p-chloranilic acid,19 which requires a liquid/liquid 
extraction.  Other methods are based on separative techniques, 
such as electrophoresis,20 gas chromatography15,21 and liquid 
chromatography,15,16 in order to reduce interferences from the 
excipients.  Due to the low solubility of TAMO in water, these 
methods require the use of organic solvents.  Liquid 
chromatography is preferred, because of its accessibility in 
hospital laboratories.  In this case, the detection is performed by 
UV-Visible absorbance15 and mass spectrometry (MS).16  This 
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last one shows higher analytical performance, but it is an 
expensive instrumentation, which requires especial care.22 
HPLC coupled with fluorescence detection (FLD) has been 
widely used to detect TAMO in biological samples, because of 
the high sensitivity, specificity and relatively low cost, compared 
to other detectors.23–27  However, it has not been previously used 
to our knowledge to analyze TAMO citrate pharmaceutical 
formulations.  As TAMO is not fluorogen, it must be previously 
activated by photo-cyclization induced by irradiation to form a 
derivative with a phenanthrene core, which shows intense 
fluorescence.28–30
We have previously developed a micellar liquid 
chromatographic (MLC) method, coupled with FLD for the 
quantification of tamoxifen in plasma with excellent results.29,30 
Anionic sodium dodecyl sulfate (SDS) was used as a surfactant, 
due to its low cost, critic micellar concentration, Krafft point 
and viscosity, as well as high solubility in water and 
biodegradability.31  This method can be adapted to analyze 
solids.32  Micellar solutions are extremely useful when dealing 
with hydrophobic compounds.  These are solubilized by 
interactions with the micelle, avoiding the use of organic 
solvents in sample preparation.33  The benefits of MLC are also 
extended to chromatographic separation.  Micellar mobile 
phases use non-polluting inorganic reagents, and reduced 
amount of alcohol (up to 12.5%).34  Besides, SDS interacts with 
the alcohol, preventing its evaporation.  As results, they are less 
toxic, less flammable, more stable and environmental-friendly 
and relatively inexpensive if compared to hydroorganic mobile 
phases.35  MLC has been useful in the determination of a large 
amount of drugs, as ergot alkaloids,36 antibiotics,37 disulfiram,38 
antidepressants,39 antianginals,40 diuretics,41 benzodiazepines, 
phenethylamines, antihistamines, vitamins and corticosteroids42 
in pharmaceutical formulations.
The aim of the work is to develop a simple, inexpensive, 
sensitive and environmentally friendly analytical method to 
measure the quantity of TAMO in pharmaceutical formulations. 
The selected technique was micellar liquid chromatography 
(using SDS as surfactant) coupled to fluorescence detection. 
The use of organic solvents would be avoided in sample 
preparation.  Tamoxifen should be eluted without interferences 
in a short analysis time.  Quantification results must be reliable 
and with low variability.  The method ought to be validated 
following the requirements of the Tripartite Harmonized ICH 
Guidelines in terms of the linear interval, linearity, limits of 
detection (LOD) and quantification (LOQ), precision, accuracy 
and robustness.43  Finally, the developed analytical method 
would be applied to verify the quantity of TAMO in commercial 
TAMO citrate tablets distributed in Spain.
Experimental
Apparatus and instrumentation
Solids were weighted with a Mettler-Toledo analytical balance 
(Greifensee, Switerland).  A Ultrasons-H bath (Selecta, Abrera, 
Spain) was used to ultrasonicate the solutions.  The pH measures 
were performed using a GLP 22 potentiometer (Crison, 
Barcelona) equipped with a combined Ag/AgCl/glass electrode. 
The samples were irradiated with a Philips original home solaria 
UV lamp (Philips, Eindhoven, The Netherlands).
The chromatograph was a Series HP-1100 system (Agilent 
Technologies, Palo Alto, CA).  It was equipped with an isocratic 
pump, a degasser, and autosampler and a fluorescence detector. 
The column was a Kromasil C18 (150 w 4.6 mm; particle size 
5 µm: pore size 100 Å, working pH range 1.5 – 7.5) from 
Sclarlab (Barcelona, Spain).  The signal was acquired by a 
personal computer connected to the chromatograph by means of 
an Agilent Chemstation Version B.01.01.  The special care 
needed when using micellar solutions as mobile phases has been 
detailed.44  Under these conditions, the column had a life span 
of nearly 1000 injections.
Chemicals
Tamoxifen standard (purity >99.5%) was purchased from 
Sigma (St. Louis, MO).  Sodium dodecyl sulfate (purity >99.0%) 
was supplied by Merck (Darmstadt, Germany).  Hydrochloride 
acid, sodium hydroxide and sodium dihidrogenphosphate 
(reagent grade), methanol and pentanol (HPLC grade) were 
acquired from Scharlab (Barcelona, Spain).  An ultrapure 
generator device (Millipore S.A.S., Molsheim, France) was used 
to purify deionized water to ultrapure water.  This ultrapure 
water was used to prepare all solutions and mobile phases.
Solutions and mobile phases
Standard solutions: a 200-mg/L stock solution of TAMO was 
prepared by solving an adequate amount of standard in few 
milliliters of methanol, and then diluting with water.  Working 
solutions were prepared by successive dilutions of the stock 
solution with 0.05 M at pH 3.  All solutions were stored at 4°C 
in the dark, and monthly renewed.
Pharmaceutical solutions: Commercially available tablets of 
TAMO were finely powdered using agate mortars.  The 
appropriate amount of pharmaceutical to prepare a 10-mg/L 
TAMO solution was weighted and introduced in a flask.  The 
solid was solved in few milliliters of methanol, and then the 
flask was filled up to the mark with a 0.05-M SDS-pH 3 
solution.  Further dilutions were performed with 0.05 M SDS at 
pH 3.
Tamoxifen solutions (standard or pharmaceuticals) were kept 
in amber flasks so as to avoid the photodegradation of the drug.
Micellar solutions: they were prepared by weighting an 
appropriate amount of SDS and sodium dihydrogenophosphate 
buffer (0.01 M) and solving them in water.  The pH was adjusted 
by adding drops of HCl or NaOH to the desired value. 
Furthermore, the adequate volume of pentanol was added and 
the volumetric flask was filled up to the mark with water.
All solutions and mobile phases were ultrasonicated to ensure 
total solubilization, and filtered through 0.45 µm nylon 
membranes (Micron Separations, Westboro, MA).
Sample treatment and chromatographic conditions
A volume of 0.1 mL of already filtered solution containing 
TAMO (standard or pharmaceutical sample), was introduced 
into a see-through 6 mm-diameter small pulled-point glass vial. 
The mixture was irradiated at 254 nm for 20 min at 40 W.  The 
vial was pasted on the irradiation source.  A volume of 0.020 mL 
of the aliquot was injected into the chromatographic system.
The elution of TAMO was performed using a mobile phase 
containing 0.15 M SDS-7% pentanol at pH 3, running through 
the C18 column at 1.5 mL/min at 40°C.  The detection was 
performed by fluorescence; the excitation and emission 
wavelengths were set at 260 and 380 nm, respectively.
Results and Discussion
Optimization of the sample treatment
The experimental procedure was taken from a previously 
published paper devoted to the analysis of TAMO in a plasma 
sample,29,30 and adapted to a different matrix: the tablet.  The 
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irradiation conditions were kept.  The filtering was performed 
before the irradiation step, taking a large volume, because the 
filtering of a small amount of sample increases the percentage 
loss of the sample.  Pharmaceutical solutions are cleaner than 
plasma samples, since they contain fewer amounts of suspended 
particles.  Therefore, it is less harmful for the column and the 
chromatographic system.  Therefore, the aliquot was not diluted 
before injection, in order to improve the sensitivity.
The composition of the micellar solution used to solve the 
tablet extraction micellar solution was optimized by considering 
the extraction efficiency.  Three micellar solutions were prepared 
at several concentrations of SDS (0.05; 0.010 and 0.15 M) and 
pH (3 and 7).  Furthermore, the same amount of powdered tablet 
was solved in them.  These prepared pharmaceutical solutions 
were analyzed, and the peak area was found similar in all cases. 
The selected SDS amount was 0.05 M in order to reduce the 
mass of reagent wasted.  The pH was 3, in order to avoid the 
change of pH when the aliquot reaches the mobile phase.
Optimization of the chromatographic conditions
A pharmaceutical solution was analyzed under the 
chromatographic conditions indicated.30  The results were found 
to be similar, but the front of the chromatogram was baseline-
like, instead of the intense protein band at ~ 4 min observed in 
plasma analysis.  No other peaks were detected.  Therefore, the 
main chromatographic conditions (stationary phase, surfactant, 
pH, wavelength detection) were kept, but the mobile phase was 
modified so as to reduce analysis time.  In this case, there is no 
risk of interference with the front of the chromatogram, 
regardless of the quick elution of tamoxifen.
The use of a more hydrophobic alcohol would increase the 
elution strength of the mobile phase; therefore, pentanol was 
used instead of butanol.  Using a mobile phase composed of 
0.15 M SDS 7% pentanol at pH 3, TAMO is eluted at ~ 3.5 min 
with an efficiency of 4587 theoretical plates and an asymmetry 
of 1.15.  Figure 1 shows a chromatogram obtained by the 
analysis of a solution of 5 mg/L TAMO solved in 0.05 M SDS 
at pH 3.
Method validation
The method was validated following the requirements of the 
ICH Tripartite Harmonized Guideline, especially devoted to the 
analysis of drugs.43  The entire validation was performed using 
standard solutions of TAMO solved in 0.05 M SDS at pH 3. 
The studied parameters were: linearity, linear range, sensitivity, 
as LOD and LOQ, inter- and intra-day accuracy, repeatability, 
intermediate precision and robustness.
a) Linearity: For linearity studies, seven TAMO solutions at 
increasing concentrations, from 0.2 to 20 mg/L, were analyzed 
by triplicate.  The calibration curve was constructed by 
correlating the peak area vs. TAMO concentration by least-
square linear regression.  The final slope, y-intercept and 
determination coefficient were:
A = (1338 t 7) [TAMO] + (10 t 60),    r2 = 0.9998,
where A is the luminescence in arbitrary units and the 
concentration is in mg/L.
LOD and LOQ were calculated as 3.3 and 10-times the 
standard deviation of the blank divided by the sensitivity.  The 
standard deviation of the blank was the standard deviation of the 
signal obtained by ten measurements of a blank solution of 
0.05 M at pH 3.  The sensitivity was the slope of the calibration 
curve.  LOD and LOQ were 70 and 200 ng/mL, respectively.
b) Accuracy and precision: These parameters were evaluated by 
analyzing (n = 6) standard solutions with 1; 5 and 10 mg/L. 
The intraday accuracy was calculated as the quotient of the 
average value of the measured concentrations and the true value. 
The repeatability was measured as the relative standard deviation 
of the signal provided by the detector.  These values were 
calculated while performing all of the analysis during a short 
time on the same day.  The interday accuracy and intermediate 
precision were calculated as the average values of intraday 
analysis performed on five different days over a 3-months 
period.  The results are given in Table 1.
In all of the studied range, the method shows low variability 
(<1.5%) and the measured concentrations were close to the 
correct values (98.8 – 101.7%), indicating the high quality of 
the quantitative results.
c) Robustness: The variation of the main chromatographic 
results (peak area and retention time) was evaluated in front of 
small changes of the main mobile phase conditions (SDS and 
pentanol concentration, pH and flow rate).  The oscillation of 
each experimental condition was separately studied.
A standard solution of 10 mg/L was used to examine the 
robustness.  For each parameter, the relative standard deviation 
of the peak area and the retention times obtained at the optimized 
value, slightly over and slightly below were calculated (n = 3 in 
each case).  The other parameters remain at their optimized 
values.  The evaluated levels and the corresponding results can 
be seen in Table 2.  The low variability in the peak area (<3.5%) 
and the retention time (<6.2%) indicates that these data are not 
Fig. 1　Chromatogram obtained by the analysis of a solution of 
5 mg/L TAMO solved in 0.05 M SDS at pH 3 under the optimized 
conditions.
Table 1　Results obtained by precision and accuracy studies
Concentration/
mg L–1
Intraday 
Accuracya, 
%
Interday 
Accuracyb, 
%
Repeatabilitya, 
%
Intermediate 
precisionb, %
 1
 5
10
101.7
 98.8
100.7
101
99.2
99.8
1.5
0.9
0.5c
1.3
1.1
0.3
a. n = 5.
b. n = 6.
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significantly affected by small variations of the chromatographic 
conditions.
Analysis of tamoxifen citrate formulations
The obtained results in validation indicate that the method is 
reliable and sufficiently sensitive.  The waste produced by the 
analyses contains mainly biodegradable and non-pollutant 
reagents (water, SDS, phosphate and sodium chloride) and only 
a small amount of toxic solvent (7% of pentanol).  Moreover, 
the entire analysis can be performed in only 30 min: estimating 
~ 5 min for sample preparation, 20 min for TAMO photo-
activation and 5 min for the chromatographic run.  Besides, it 
used relatively inexpensive instrumentation and reagents. 
Therefore, the analytical methodology is useful for the routine 
analysis of tamoxifen in formulations.
The content of several TAMO citrate formulations purchased 
from a local chemist were analyzed (n = 3).  Since the maximal 
accuracy and precision was obtained at 10 mg/L, the 
formulations were diluted in 0.05 M SDS-pH 3 to reach this 
concentration.  This coincides with the central value of the 
calibration range, where the statistical error is minimized.45  In 
all of the obtained chromatograms, TAMO was eluted without 
overlapping with other compounds of the matrix, then proving 
the specificity of the methodology.
The obtained label claims are given in Table 3.  The 
chromatogram corresponding to the analysis of NOVALDEX 10 
mg sample is shown in Fig. 2.  The measured amount was in all 
cases similar to those mentioned on the wrapper.
Advantages of the method
The main feature of the analytical method is strong 
simplification of the sample preparation, which is expedited to 
solubilization, photoactivation, filtration and injection. 
Therefore, chemical derivatization and liquid/liquid 
extraction17–19 are avoided.  The elimination of intermediate 
steps reduces the probability of any operator error, and thus 
improving the robustness and reproducibility of the method. 
Other feature is that the sample is quantitatively transferred to 
the chromatographic system, whereas in,17–19 the analyte is 
previously separated from the matrix.  This increases the 
recovery and the precision, because the yielding of the reaction 
and extraction can show a slight variability, which is normally 
under 100%.
Another feature of the method is a reduction of the volume of 
organic solvent required.  Sample preparation is performed in 
aqueous solutions and inorganic biodegradable reagents, 
whereas in previously issued methods the use of a toxic organic 
solvent is required to solubilize the sample15,16 and to perform 
liquid/liquid extraction.17–19  Moreover, the present method uses 
a mobile phase with only 7% of pentanol, whereas the other 
methods use up to 30%15 and 95%16 of acetonitrile.  Therefore, 
the health danger related to the handling of hazardous and 
flammable compounds, as well as the environmental impact, are 
Table 2　Evaluation of the robustness of the MLC method 
(n = 3)
Mobile
phase parameter Level
Retention time
 (RSD, %)
Peak area
(RSD, %)
Concentration SDS/M
Pentanol, %
pH
Flow/mL min–1
0.145 – 0.155
6.9 – 7.1
2.9 – 3.1
1.45 – 1.55
3.9
4.5
2.1
6.2
2.4
3.5
1.2
1.4
Table 3　Label claims obtained for commercial TAMO citrate 
tablets
Pharmaceutical formulation (Supplier)
Expected 
tamoxifen 
quantity/
mg
Label 
claim, %
NOLVADEX  10 mg (Astrazeneca, 
Macclesfield, UK)
10 99.2
NOLVADEX  20 mg (Astrazeneca) 20 100.4
TAMOXIFENO CINFA EFG Comp.  10 mg 
(Cinfa, Plamplona, Spain)
10 98.7
TAMOXIFENO CINFA EFG Comp.  20 mg 
(Cinfa)
20 99.0
TAMOXIFENO EDIGEN EFG Comp.  
10 mg (Edigen, Madrid, Spain)
10 99.8
TAMOXIFENO EDIGEN EFG Comp.  
20 mg (Edigen)
20 101.0
TAMOXIFENO RATIOPHARM EFG 
Comp.  10 mg (Ratiopharm, Madrid, Spain)
10 100.4
TAMOXIFENO SANDOZ Comp.  
10 mg(Sandoz Farmaceutica, Aravaca, 
Spain)
10 98.4
TAMOXIFENO SANDOZ Comp.  20 mg 
(Sandoz Farmaceutica)
20 98.9
TAMOXIFENO TORA Comp.  10 mg (Tora 
Laboratories, Madrid, Spain)
10 99.7
TAMOXIFENO TORA Comp.  20 mg (Tora 
Laboratories)
20 100.2
TAMOXIFENO UR EFG Comp.  10 mg 
(Uso Racional S.L., Madrid, Spain)
10 98.7
TAMOXIFENO UR EFG Comp.  20 mg 
(Uso Racional S.L.)
20 99.8
YACESAL Comp.  10 mg (Laboratorios 
Smaller S.A., Madrid, Spain)
10 100.4
YACESAL Comp.  20 mg (Laboratorios 
Smaller S.A.)
20 99.7
Fig. 2　Chromatogram obtained by the analysis of a NOLVADEX 
10 mg tablet under the optimal conditions.
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minimized.
The application of micellar liquid chromatography also 
introduces important advantages over spectrophotometric 
methods as well as hydroorganic-HPLC and LC-MS-MS.  The 
use of a separation technique reduces the probability of 
interference, and thus improves the specificity, if compared to 
direct spectrophotometry.17–19  Moreover, the use of a 
photoactivation reaction and MLC-FLD analysis allows one to 
reach a lower LOD than that by derivatization-spectrophotometric 
analysis19 (70 ng/mL and 2.75 µg/mL, respectively).  In,16 the 
elution is performed in 9.9 min using a gradient, whereas in the 
present work the tamoxifen is eluted in 3.5 min under the 
isocratic mode.
The here-detailed method allows one to perform the analysis 
at a lower price, because of shortens of both experimental 
procedures, compared to17–19 and the chromatographic run,15,16 
the use of fewer amounts of reagents than in15–19 and the 
utilization of basic chromatographic instrumentation, instead of 
expensive LC-MS-MS.16  Moreover, the use of isocratic mode 
instead of a gradient,15,16 facilitates the successive analysis of a 
large number of samples.  For these reasons, the proposed 
method is available to laboratories with less economic power, 
and is useful for routine analysis.
Conclusions
Micellar liquid chromatography is an appropriate technique to 
determine the amount of active principle (tamoxifen) in the 
TAMO citrate formulations.  The main advantage of the method 
is simplification of the sample preparation.  Due to solubilization 
of the excipients and the analyte in micellar media, tedious and 
time-consuming extraction and clean-up steps are not required. 
TAMO was eluted without interference from the matrix 
compounds.  The concentration of tamoxifen in the formulations 
is measured with high reliability, due to the adequate values of 
accuracy, precision and robustness.  The analyses can be 
performed in less than 30 min at low cost.  Moreover, the 
method is environmentally friendly, since it uses biodegradable 
inorganic salts and only a small amount of toxic organic solvent.
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